Actively Enrolling Wet AMD Clinical Trials
Wet Macular Degeneration
Wet age-related macular degeneration (Wet AMD) is characterized by the development of irregular blood vessels beneath the macula. Left untreated, these vessels can permanently damage the delicate retinal tissue. Prior to approximately 2005, effective treatment options were limited, often resulting in significant vision loss for affected patients.
However, thanks to clinical trials conducted in the early 2000s, we now have highly effective, minimally invasive, and nearly painless treatments. Unfortunately, these treatments require frequent repetition—approximately every 10 weeks—to maintain vision. This can be burdensome for both patients and caregivers.
Excitingly, we are actively collaborating in the development of the next generation of treatment options. These include longer-lasting and even more effective molecules, as well as groundbreaking gene therapy that holds the potential to essentially cure some patients.
Clinical trials offer hope during these transformative times. Below, we highlight some of the trials in which we participate and that are available to our patients. If you believe you, a friend, or a family member might be a suitable candidate, please don’t hesitate to reach out to our research team at [email protected].
AAVIATE
REGENXBIO (Rockville, MD)
Phase II trials evaluating suprachoroidal delivery of gene therapy for wet AMD
PI: Nikolas JS London, MD FACS
Status: Active and enrolling
NIH registration: Clinicaltrials.gov
Sponsor website: REGENXBIO
Contact: [email protected]
4-FRONT 1
4D Molecular Therapeutics (Emeryville, CA)
4FRONT-1 is a Phase 3 multicenter, randomized, double-masked, aflibercept 2 mg (Q8W) comparator-controlled study of intravitreal 4D-150 in wet AMD.
PI: Michael Ammar, MD
Status: Active and enrolling
NIH registration: Clinicaltrials.gov
Sponsor website: 4D Molecular Therapeutics
Contact: [email protected]
Achieve
Abbvie (North Chicago, IL)
Achieve is a randomized, controlled, partially masked, phase 3b study to assess the injection burden, efficacy, safety, and long-term preservation of visual acuity of Surabgene Lomparvovec (ABBV-RGX-314) in a real-world context in subjects with neovascular age-related macular degeneration (nAMD)
PI: Nikolas JS London, MD FACS
Status: Active and enrolling
NIH registration: Clinicaltrials.gov
Sponsor website: Abbvie
Contact: [email protected]
Years in Practice in San Diego
We've been leading the way in retinal care and clinical research since 1979.